Original Research ARTICLE
Posterior Cortical Atrophy: Does Complaint Match the Impairment? A Neuropsychological and FDG-PET Study
- 1ToNIC, Toulouse NeuroImaging Centre, University of Toulouse, Inserm, UPS, Toulouse, France
- 2Department of Neurology, University Hospital of Toulouse, Toulouse, France
- 3Department of Nuclear Medicine, University Hospital of Toulouse, Toulouse, France
Objective: Posterior Cortical Atrophy (PCA) is a neurodegenerative disease characterized predominantly by visual impairment. However, diagnosis of PCA remains complicated with an interval of several years between initial reporting of symptoms and diagnosis. The aim of the present study is to define if patients' visual and gestural complaints are consistent with their clinical profile.
Method: An evaluation of daily visual problems as well as a full neuropsychological assessment and FDG-PET were performed in 15 PCA patients. We compared glucose metabolism between these PCA patients and 18 healthy controls. Correlation analyses were conducted in PCA patients between visual and gestural complaint, clinical impairments, and brain glucose metabolism.
Results: Major impairment of cognitive functions was detected in PCA patients specifically in visual domains. Positive correlations were found between visual impairments and hypometabolism in the right temporo-parieto-occipital cortices. However, no correlation was found between complaint and visual impairment in PCA patients.
Discussion: Our main results suggest a consistent relationship between clinical impairment and brain metabolism. However, the patient's complaint and visual performance are not linked. Combining the literature and our results, it seems that patients are generally aware of difficulties but misinterpret them. This misinterpretation may be responsible for the delayed diagnosis.
Posterior cortical atrophy (PCA) is characterized by an insidious onset, gradual progression and prominent early disturbance of visual functions (1). Currently, PCA is considered as an atypical form of Alzheimer's disease (AD) (2, 3) with biomarkers consistent with Alzheimer's pathophysiology in 80% of PCA cases (4). However, PCA diagnosis remains complex and may take several years after first complaint by the patient (5). As the first symptoms are visual, patients are initially referred to an ophthalmologist. Ophthalmological examination is normal in this condition. Neurological expertise is subsequently required, sometimes years after the first symptoms (6). One hypothesis to explain this delay could be a misunderstanding of their impairments by the patients themselves. Although insight seems to be preserved in PCA patients (1), this aspect has never been clearly investigated and literature of PCA clinical cases remains controversial (2, 7). In order to identify patients' complaints more clearly and facilitate the diagnosis for ophthalmologists and neurologists, Croisile and Mollion (6) proposed the PCA questionnaire (PCA-Q) to evaluate visual and gestural complaints (6). The authors reported significantly more visual and gestural complaints in PCA patients than in typical AD patients and healthy controls. However, the relationship between complaint and gnosis and praxis in PCA patients has not yet been established.
Two clinical variants of PCA including ventral and dorsal PCA are described in the literature. Visuospatial functions, impairment, apraxia, agraphia, features of Balint syndrome (optic ataxia, simultagnosia, ocular apraxia), or Gerstman syndrome (digital agnosia, acalculia) are characteristic of dorsal PCA variant. Impairment of visuoperceptive functions, visual agnosia, and prosopagnosia are characteristic of the ventral PCA variant (8).
Clinical symptoms have been linked to cortical atrophy and hypometabolism in dorsal (occipito-parietal) and ventral (occipito-temporal) regions (9, 10). To explore the link between visual deficits and cortical thickness measured using MRI in 21 PCA patients, Lehmann et al. (11) reported a lower cortical thickness in occipito-temporal and occipito-parietal areas in relation to visuoperceptual and visuospatial deficits, respectively (11). PCA is also characterized by major hypometabolism in occipital, parietal associative as well as temporo-parietal cortices (4, 12, 13). In a study using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG), Nestor et al. (14) reported a change in metabolism in occipito-parietal regions in PCA patients presenting with predominant visuospatial deficits compared to healthy controls. Asymmetry indicative of more pronounced hypometabolism in the right hemisphere was also reported (14).
The main objective of this study was to understand whether patient complaint reliably reflects cognitive impairment in PCA patients. We also explored the link between complaint and brain glucose metabolism since literature suggests that a decrease in brain glucose metabolism explains cognitive impairment in PCA (11, 14). An important first step was to confirm the existence of such a link between clinical impairments and brain glucose metabolism in our population. We assessed visual and gestural complaint by the Croisile and Mollion questionnaire (6), clinical impairment by a comprehensive neuropsychological evaluation and brain metabolism using FDG-PET in 15 PCA patients.
Fifteen PCA patients were recruited through the outpatient Memory Clinic of The Neurology Department of Toulouse University Hospital (France). The clinical diagnosis of PCA was carried out in accordance with the clinical criteria provided by Crutch et al. (4) and was retrospectively confirmed by the revised 2017 criteria (8): progressive decline in visual abilities, relatively intact memory, and language functions in the early stages and atrophy of posterior regions of the brain (4). All visual deficits were explained by cognitive and non-ophthalmic impairments. Cerebrospinal fluid (CSF) samples were obtained by lumbar puncture from all patients. CSF levels of total Tau (T-Tau), phospho Tau (p-Tau), Aβ42, and Aβ40 were measured. Ratios were also calculated from these biomarkers, including the Innotest Amyloid Tau Index [IATI = Aβ42/(240 + (1.18 × T-Tau)] and the Aβ42/Aβ40 ratio (15). PCA patients were deemed to have AD pathophysiology if they met the following criteria: phospho-Tau ≥60 pg/mL and Innotest Amyloid Tau Index ≤ 0.8 or Aβ42/Aβ40 <0.045 (16).
For the purpose of imaging analysis, 18 healthy controls (HC) matched in age, gender and education were enrolled in this study. The HC had no history or clinical evidence of psychological or neurological disorders and were not cognitively impaired.
This study was approved by the local ethics committee (Comité de Protection des Personnes Sud-Ouest et Outre-Mer I) and the French Agency for Safety and Security of Medical Devices (Agence Française de Sécurité Sanitaire des Produits de Santé, reference A90605-58).
Visual and Gestural Complaint Assessment
The PCA-Q was completed by each PCA patient (6). The PCA-Q comprises 32 questions regarding daily visual and gestural difficulties (see French and English versions of the questionnaire in Supplementary Figures 1A,B, respectively). This questionnaire covers visual and gestural domains and comprises 32 items, sub-divided into 12 sections. For each item, a score of 1 is allocated if a complaint is reported and a score of 0 in the absence of any complaint. A visual complaint sub-score (/15) and a gestural complaint sub-score (/9) were computed based on this questionnaire. The items that constitute each sub-score are detailed in Appendix A1 (Supplementary Material).
Assessment of Visual Functions
PCA patients completed an assessment of visual and gestural functions. Due to important impairments in these domains, some tests could not be completed by all patients (interrupted after the example phase). Only tests used for the statistical analysis are described below (for the complete description and results of visual and gestural assessment (see Appendix A2 in Supplementary Material and Supplementary Table 1, respectively).
Visual functions were assessed using tests from the Visual Object and Space Perception battery (VOSP) battery (17, 18). Primary visual capacities were assessed with the Shape Detection Screening test. Visual perceptive functioning was assessed with the 2 following tests: the Silhouettes test, assessing the capacity to identify objects depicted from unusual perspectives, and the Object Decision test, assessing the capacity to select the silhouette drawing of a real object among three silhouettes of non-sense objects. Visual spatial functions were evaluated with the Dot counting test to identify the number of stimuli presented in random array and the Position Discrimination test to discriminate relative spatial position. Each visual test started with an example phase. For each test, patients who failed at the example phase were considered untestable. Tests with more than 5 untestable patients (representing 1/3 of patients) were removed from the analyses (see details in Appendix A2 in Supplementary Material).
To address the problem of missing data due to untestable patients and in agreement with the previous study (11), raw scores were transformed into rank scores. Patients with a missing score were assigned the score of the lowest performance of the group minus 1 point. Thus, patients who did not pass the example phase are given a lower score than those who completed the test. Raw scores were then converted to rank scores among the 15 PCA patients, ranging from 1 for the lowest performance to 15 for the highest performance. A visual performance score (/75) was computed from the rank sum (/15) of the five following tests: Shape Detection, Dot Counting, Position Discrimination, Silhouettes, and Object Decision.
Assessment of Gestural Functions
Gestural functions were evaluated by Mahieux's test (19) with right and left symbolic gestures and pantomimes. A gestural performance score (/20) was derived from the sum of the raw scores in the following Mahieux's tests: symbolic gestures to the right (/5) and left (/5), and pantomimes (/10).
Other Neuropsychological Assessment
Patients underwent the Mini-Mental Scale Examination (MMSE) (20) to assess global cognitive functions, and the Free and Cued Selective Reminding Test (FCSRT) (21) to assess verbal memory. The Digit Span Forward and Backward test [Weschler Adult Intelligence scale III—WAIS III, (22)] was used to assess verbal working memory. Phonemic and semantic fluency (23) were used to assess initiation and the Similarities test [WAIS-IV, (24)] for abstract verbal conceptualization. A dictation task (writing of 5 regular and 5 irregular words and 3 sentences) and a reading task (8 regular words, 8 irregular words and 8 pseudo-words) were used to assess agraphia and alexia, respectively.
All 18 HC and 15 PCA patients underwent an [18F]FDG-PET scan. Acquisitions were performed on a Biograph 6 TruePoint Hirez (Siemens Medical Solutions, Munich, Germany) hybrid PET/computed tomography (CT) scanner (3D detection mode, producing images with 1 × 1 × 1.5 mm voxels). Cerebral emission scans began around 20 min after the injection of 1.85 MBq/kg weight of [18F]FDG, and lasted 10 min. A structural T1-weighted image was also recorded for each participant.
Data Processing and Analyses
The pre-processing of [18F]FDG-PET data was performed using Statistical Parametric Mapping software (SPM12; Wellcome Trust Centre for Neuroimaging, London, UK) running on MATLAB (Version 2016b, MathWorks, Inc.). For each participant, Standardized Uptake Value (SUV) images corrected for body weight, the rescale slope and the injected dose (corrected by the interval between injection time and scan time) (25) were created. Rigid co-registration onto the corresponding T1-weighted image was then applied. The partial volume effect using the T1-weighted image was corrected with the PET-PVE12 toolbox (26) running on MATLAB. Spatial normalization of [18F]FDG PET images in the MNI space was achieved using the [18F]FDG PET template developed by Della Rosa et al. (27). Normalized images were then scaled quantitatively using the vermis of the cerebellum as the reference region to obtain the SUV ratio (SUVR). Finally, SUVR images were smoothed with an 8 mm full width at half maximum (FWHM) Gaussian Kernel.
Demographic and Neuropsychological Data
All statistical analyses on demographics as well as on cognitive, visual and gestural performance were performed using the R project package, version 3.5.1. A threshold of p < 0.05 was used for significance.
Intergroup comparisons on age and level of education were performed using Student's t-test for independent samples and on sex with Chi-Square test.
In order to investigate the relationship between complaint and deficits, Spearman correlations were investigated between the PCA-Q visual complaint sub-score and the visual performance score, and between the PCA-Q gestural complaint sub-score and the gestural performance score.
Brain Imaging Data
Intergroup comparisons using voxel-based analysis (voxel level, p < 0.05, FWE-corrected, cluster > 50) were performed for [18F]FDG-PET imaging. In order to investigate metabolism asymmetry, median SUVR were extracted for the following 7 left and right regions of interest (28) from the DTK (Desikan-Killiany-Tourville) atlas (29): frontal, lateral temporal, medial temporal, lateral parietal, medial parietal, and occipital cortices. Details of these ROIs are reported in Supplementary Table 2. A hemispheric asymmetry index (AI) was then calculated for each ROI using the formula AI [%] = −200 × (R – L)/(R + L) (30). Positive scores indicate more pronounced hypometabolism in the right hemisphere while negative scores indicate more pronounced hypometabolism in the left hemisphere. The difference in AI between healthy subjects and PCA patients was assessed using a Wilcoxon-Mann-Whitney signed-ranked test.
Voxel wise correlations were performed in PCA patients between [18F]FDG uptake and the following variables (voxel level p < 0.001, cluster > 50 voxels): visual performance score (/75), gestural performance score (/20), PCA-Q visual sub-scores and PCA-Q gestural sub-score. In order to investigate more precisely the relationship between metabolism and visuoperceptive and visuospatial functions, voxel-wise correlations were also conducted between [18F]FDG uptake and each of the 5 variables constituting the visual performance score (voxel level p < 0.001, cluster > 50 voxels). Correlations using regions of interest (ROI) were also established between the median SUVR of each ROI (left and right) and the afore-mentioned variables.
PCA patients and HC were comparable in age (PCA: 66 , HC: 68 , p = 0.38), level of education in years (PCA: 12 , HC 11.5 , p = 0.898), and sex (PCA: 7 females/8 males, HC: 12 females/6 males, p = 0.435). Among the 15 patients, 12 had CSF biomarkers consistent with amyloid pathology. Three patients presented with normal levels of amyloid and tau protein (Table 1).
All patients reported a cognitive complaint at the PCA-Q with a minimal complaint of 8/32 and a median value of 17/32.
Details on the neuropsychological assessment are reported in Supplementary Table 3. With regard to the 5 visual tests, more than half of the patients systematically performed below the 5th percentile (between 60 and 100%). For gestural domains, between 26.6 and 40% of the patients performed below the 5th percentile.
Similarly, no correlation was established between visual complaint and visual performance (r = −0.34, p = 0.21) (see Figure 1A), and between gestural complaint and gestural performance (r = −0.15, p = 0.60) (see Figure 1B).
Figure 1. Correlation between performance and complaint in visual (A) and gestural (B) modality. The correlation was carried out using Spearman's correlation test with a threshold of p < 0.05.
Hypometabolism was detected in PCA patients compared to healthy subjects in the temporo-parieto-occipital cortices, frontal areas (bilateral frontal eye field) and cerebellum (vermis excluded) (see Figure 2C). More severe hypometabolism was found in the lateral occipital compared to the medial occipital cortex in PCA patients (see Figures 2A,B), a signature referred to as “occipital tunnel sign.” Hypometabolism was predominant in the right hemisphere, with significantly lower right uptake in the medial and lateral temporal cortex, the medial and lateral parietal cortex, and occipital cortex (see Figures 2A, 3). Details on FDG uptake in each hemisphere as well as AI are reported in the Supplementary Table 4.
Figure 2. Brain metabolism in PCA Patients (A), Healthy Controls (B), and comparison between PCA patients and Healthy Controls (C) measured by [18F] FDG PET. “Occipital tunnel sign” is represented by preserved uptake in the medial occipital areas (red arrows) in comparison to lateral occipital (blue arrows). Metabolism asymmetry with right predominance (blue arrows) is also found in PCA patients. (A,B) represent the mean of PCA patients (n = 15) and healthy controls (n = 18), respectively. The statistical threshold for group comparison is pFWE-corr < 0.05 (k > 50 voxels). PCA, posterior cortical atrophy; SUVR, Standard Uptake Value Ratio.
Figure 3. Hemispheric asymmetry index of [18F]FDG uptake in regions of interest in healthy subjects (n = 18) and PCA patients (n = 15). Dot plot representing asymmetry index [%] using the formula: −200 × (R – L)/(R + L). Red dots represent the median for each group. Differences between healthy controls and PCA patients were assessed using the Wilcoxon-Mann-Whitney signed-ranked test. *p < 0.05. R, Right; L, Left; PCA, Posterior Cortical Atrophy.
Regarding visual functions, performance in the Shape Detection, Silhouettes and Dot Counting tests was positively correlated to [18F]FDG uptake in the right parieto-occipital cortex using the voxel-wise approach (see Table 2 and Figure 4). Similar results were recorded using the ROI approach (see Table 3). In addition, a positive correlation was found between performance in the Object Decision test and [18F]FDG uptake in the right lateral parietal cortex using the ROI approach, but not using a voxel-wise approach (see Table 3). No correlation was found between performance in the Position Discrimination test and [18F]FDG uptake, regardless of the approach used.
Table 2. Areas of the brain where metabolism correlates with visual and gestural functions in PCA patients.
Figure 4. Areas of the brain where metabolism correlates with primary visual functions (Shape detection Screening Test), visuoperceptive (Silhouettes Test), visuospatial (Dot Counting Test), and gestural functions in PCA patients. The statistical threshold is puncorr < 0.001 (k > 50 voxels). Correlations on the right panel are performed on the whole cluster considered (i.e., the right superior parietal cortex for visual functions and the left supramarginal gyrus for gestural functions).
Table 3. Correlation matrix between metabolism and visual functions, gestural functions, visual complaint, and gestural complaint.
Regarding gestural functions, gestural performance was positively correlated to [18F]FDG uptake in the left supramarginal cortex and cerebellum (vermis excluded) using the voxel-wise analysis (see Table 2 and Figure 4) and uptake in the left lateral parietal and the bilateral medial parietal cortex using the ROI approach (see Table 3).
Visual complaint was negatively correlated to [18F]FDG uptake in the right cerebellum (vermis excluded) (x: 36, y:−70, z: −24; k = 155 voxels; T = 5.25) and positively correlated to [18F]FDG uptake in the left planum polare of the superior temporal gyrus (x: −42, y: −22, z: −4; k = 296 voxels, T = 6.81). No significant correlation was established with the ROI approach. Similarly, no correlation was found between gestural complaint and metabolism, regardless of approach.
The main aim of this study was to explore complaint, cognitive deficits and neuronal substrates in PCA patients. We found that the greater the impairment in terms of visual and gestural performance, the greater the hypometabolism in the temporo-parieto-occipital regions of the brain. However, no correlation between complaint and performance was established for visual and gestural domains.
Consistent with the previously described metabolic pattern of PCA (12, 13, 31), major hypometabolism was observed in the temporo-parieto-occipital cortex in patients compared to healthy subjects. “Occipital tunnel sign,” characterized by a relatively preserved metabolism in the medial occipital in comparison to the lateral occipital cortex was also found in our patients (32). This specific pattern is notably found in PCA and Dementia with Lewy Bodies (LDB) and could be useful to distinguish them from Alzheimer's disease (32). Metabolic hemispheric asymmetry is also found in PCA contrary to LDB (12, 33). In agreement with previous studies (14, 28), we found metabolic hemispheric asymmetry with right predominance in parietal and occipital cortices in PCA patients. Nestor et al. (14) postulated that hypometabolism predominance for the right or left hemisphere could be attributed to the choice of PCA patient recruitment (14). Left-sided hypometabolism is associated with additional deficits such as aphasia whereas major right hypometabolism could be indicative of a “purer” form of the PCA syndrome. In line with this hypothesis, Magnin et al. (34), explored logopenic syndrome in PCA (34). They reported no metabolic predominance of the left or right hemisphere in PCA patients presenting language disorders. However, patients who did not present logopenic syndrome displayed isolated right parieto-temporo-occipital hypoperfusion. In our study, the right hemisphere asymmetry observed may be the marker of a typical form of PCA but specific language assessments would have been helpful to confirm this hypothesis.
Based on the clinical classification revised by Crutch et al. (8), all our patients are considered as pure PCA with 12 patients defined as PCA-AD. Three patients did not present biomarkers consistent with AD pathology and may correspond to other pathophysiologies such as PCA-LBD or PCA-CBD (Cortico Basal Degenerarion) (8). Some authors have investigated amyloid and tau protein distribution using imaging in PCA patients. Amyloid was distributed diffusely throughout the neocortex in PCA patients (35) and did not differ from typical AD patients (36). However, localization of tau ligand retention seems to better correlate with hypometabolism patterns. Ossenkoppele et al. reported greater hypometabolism and greater aggregation of tau in PCA patients, as measured by [18F]AV1451 PET. Both are correlated and a strong overlap is reported in the right hemisphere and in the occipito-parietal cortex in particular (28). Other studies also reported an alteration of white matter in this pathology (37, 38). Cerami et al. even suggested that these alterations leading to a deafferentation could be at the origin of hypometabolism in PCA patients and therefore explain why the pattern of hypometabolism is more extensive than that of atrophy. Deafferentation processes within the occipital-parietal-frontal network may also explain visuospatial and visuoperceptive impairments (37). In our study, visual spatial deficits were not only associated with hypometabolism in the parietal cortex (bilateral superior supramarginal) but also in the occipital cortex. On the other hand, for perceptive deficits, a voxel-wise approach also suggested an association with decreased metabolism in the right inferior temporal gyrus in addition to superior parietal hypometabolism.
An alteration in temporal functioning in relation to visual perceptive tasks (ventral pathway), and in parietal functioning in relation to visuospatial tasks (dorsal pathway), have already been reported in the literature (11, 14). In our study, metabolism in the right superior parietal cortex was correlated with both perceptive and spatial visual modalities, and is highlighted via two different approaches (i.e., voxel-wise and ROI correlations). The constant involvement of this parietal cortex, already reported (13, 39), suggests a primary alteration in the parietal area during the initial stages of the disease, tending to extend to more temporal regions at later stages (39). Two recent longitudinal studies confirm these later changes with atrophy that tends to increase in superior temporal and middle frontal gyrus during the course of the disease (40, 41). In terms of gestural functions, performance was linked to metabolism in the left supramarginal gyrus. This result is consistent with the literature and suggests that this region is involved in the perception of space and location of limbs (42).
Croisile and Mollion reported a PCA patient's complaint comparable to ours (PCA-Q mean = 18.5/32 in their study vs. PCA-Q mean = 17.4 in our sample) with a minimum complaint score of 9/32 whereas their AD patients and healthy controls did not report any difficulties with maximum complaint scores of 8/32 and 6/32, respectively (PCA-Q mean AD patients: 2.7; mean Healthy Controls: 0.97) (6). However, despite this complaint and the presence of poor visual and gestural performance, we did not find any direct link between the two. One possible hypothesis to explain the absence of correlation between them is the lack of awareness of self-cognitive impairment in the patients enrolled in our study. This phenomenon has already been described in typical Alzheimer's disease (43) with the implication of temporal (44), frontal (45), or cingulate cortex functioning (46). In PCA syndrome, patients are described as being aware of their visual and gestural impairment. This continuing insight into PCA patients was initially reported by Benson et al. (1) with 5 clinical cases (1). Since then, an examination of the literature has revealed that insight is preserved in PCA patients but, in most cases, the principle study by Benson et al. (1), is mostly cited (5, 39) and never really studied. Tang-Wai et al. reported the lack of insight in 2 out of 40 PCA patients in 2004 (2). In 2012, Everhart et al. reported the PCA case of a 56-year-old woman who initially presented anxiety and panic-like symptoms but no insight into the severity of the cognitive impairment (7). Some studies report that unawareness of impairments is associated with increased apathy but lower depression in AD patients whereas PCA patients seem conversely present preserved insight with less apathy (47) but higher depression than AD patients [Mendez et al. (48), see Montembeault et al. (49) for review]. In our sample, we observed patients presenting with the same level of difficulty but a different level of complaint. For instance, looking at the cognitive profiles of our patients 1 and 5 (see Table 1), we observed that global cognitive assessment (MMSE) and visual impairment were comparable between the two, but their respective level of visual complaint differed (scores of 6/15 and 14/15 for patient 1 and 5, respectively). The misunderstanding of these difficulties might account for the lack of correlation between complaint and performance. As reported by Everhart et al. patients may be aware of their difficulties but are not able to correctly evaluate them or assess their severity (6, 7). This misinterpretation of difficulties in PCA patients may also account for the delayed diagnosis. In future studies, the PCA-Q could also be completed by the caregiver. The absence of correlation could also be attributed to the lack of statistic power. Given the relative rare nature of this condition, only 15 patients were enrolled in the study.
Finally, we sought to explore the relationship between metabolism and visual and gestural complaint. There have been reports of left superior temporal gyrus involvement in auditory short-term memory (50) and both the perception and production of speech (51). Significant impairment of visual functions could lead to the establishment of compensatory mechanisms in these PCA patients. However, the level of complaint registered may be influenced in some patients by the difficulty in characterizing the impairment or gauging its severity, and thus does not clearly reflect the actual symptoms. The relationship between visual complaint and cerebral metabolism is likely to reflect more complex mechanisms that cannot be deciphered from the present data.
We explored the relationship between complaint, cognitive performance, and neuronal substrates in PCA patients. Despite the presence of visual and gestural complaints and visual and gestural impairments, no relationship was found between complaint and performance. We therefore believe that the misinterpretation of difficulties is a potential cause of delayed diagnosis. The ability to diagnose PCA therefore remains a challenge for clinicians as novel disease-modifying therapies dedicated to the initial stages of AD are being developed. PCA patients must be diagnosed as early as possible in order to benefit from this future treatment.
Data Availability Statement
The datasets generated for this study are available on request to the corresponding author.
The studies involving human participants were reviewed and approved by Comité de Protection des Personnes Sud-Ouest et Outre-Mer I. The patients/participants provided their written informed consent to participate in this study.
LG analyzed, interpreted the data, and drafted the manuscript for intellectual content. CC, PPa, and BP had a major role in the acquisition of data. LS-A revised the manuscript for intellectual content. PPé and JP conceptualized the study and revised the manuscript for intellectual content.
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
The authors thank the patients and control participants who took part in this study, as well as the promoter of this study, Toulouse University Hospital (CHU).
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fneur.2019.01010/full#supplementary-material
2. Tang-Wai DF, Graff-Radford NR, Boeve BF, Dickson DW, Parisi JE, Crook R, et al. Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy. Neurology. (2004) 63:1168–74. doi: 10.1212/01.WNL.0000140289.18472.15
3. Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol. (2014) 13:614–29. doi: 10.1016/S1474-4422(14)70090-0
6. Croisile B, Mollion H. Q-ACP: un questionnaire d'é valuation des plaintes visuelles et gestuelles des patients ayant une atrophie corticale posté rieure Q-ACP: a questionnaire for evaluating visual and gestural complaints in patients with posterior cortical atrophy. Rev Neurol. (2010) 167:485–94. doi: 10.1016/j.neurol.2010.11.003
7. Everhart DE, Highsmith JM, Davis CE. Posterior cortical atrophy: a case study of benson's syndrome that initially presented as anxiety disorder. Appl Neuropsychol. (2012) 19:229–36. doi: 10.1080/09084282.2012.686791
8. Crutch SJ, Schott JM, Rabinovici GD, Murray M, Snowden JS, Van Der Flier WM, et al. Consensus classification of posterior cortical atrophy on behalf of the Alzheimer's association ISTAART atypical Alzheimer's disease and associated syndromes professional interest area. Alzheimers Dement. (2017) 13:870–84. doi: 10.1016/j.jalz.2017.01.014
9. Alves J, Soares JM, Sampaio A, Gonçalves ÓF. Posterior cortical atrophy and Alzheimer's disease: a meta-analytic review of neuropsychological and brain morphometry studies. Brain Imaging Behav. (2013) 7:353–61. doi: 10.1007/s11682-013-9236-1
11. Lehmann M, Barnes J, Ridgway GR, Wattam-Bell J, Warrington EK, Fox NC, et al. Basic visual function and cortical thickness patterns in posterior cortical atrophy. Cereb Cortex. (2011) 21:2122–32. doi: 10.1093/cercor/bhq287
12. Whitwell JL, Graff-Radford J, Singh TD, Drubach DA, Senjem ML, Spychalla AJ, et al. 18F-FDG PET in posterior cortical atrophy and dementia with lewy bodies. J Nucl Med. (2017) 58:632–8. doi: 10.2967/jnumed.116.179903
13. Kas A, De Souza LC, Samri D, Bartolomeo P, Lacomblez L, Kalafat M, et al. Neural correlates of cognitive impairment in posterior cortical atrophy. Brain. (2011) 134:1464–78. doi: 10.1093/brain/awr055
14. Nestor PJ, Caine D, Fryer TD, Clarke J, Hodges JR. The topography of metabolic deficits in posterior cortical atrophy (the visual variant of Alzheimer's disease) with FDG-PET. J Neurol Neurosurg Psychiatry. (2003) 74:1521–9. doi: 10.1136/jnnp.74.11.1521
15. Wiltfang J, Esselmann H, Bibl M, Hüll M, Hampel H, Kessler H, et al. Amyloid β peptide ratio 42/40 but not Aβ42 correlates with phospho-Tau in patients with low- and high-CSF Aβ40 load. J Neurochem. (2007) 101:1053–9. doi: 10.1111/j.1471-4159.2006.04404.x
16. Wallon D, Rousseau S, Rovelet-Lecrux A, Quillard-Muraine M, Guyant-Maréchal L, Martinaud O, et al. The french series of autosomal dominant early onset alzheimer's disease cases: mutation spectrum and cerebrospinal fluid biomarkers. J Alzheimer's Dis. (2012) 30:847–56. doi: 10.3233/JAD-2012-120172
17. Rapport LJ, Millis SR, Bonello PJ. Validation of the Warrington theory of visual processing and the visual object and space perception battery. J Clin Exp Neuropsychol. (2002) 9800:1380–3395. doi: 10.1076/jcen.18.104.22.1689
18. Bonello P, Rapport L, Millis S. Psychometric properties of the visual object and space perception battery in normal older adults. Clin Neuropsychol. (1997) 11:436–42. doi: 10.1080/13854049708400475
19. Mahieux-Laurent F, Fabre C, Galbrun E, Dubrulle A, Moroni C. Validation of a brief screening scale evaluating praxic abilities for use in memory clinics. Evaluation in 419 controls, 127 mild cognitive impairment and 320 demented patients. Rev Neurol. (2009) 165:560–7. doi: 10.1016/j.neurol.2008.11.016
20. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. (1975) 12:189–98. doi: 10.1016/0022-3956(75)90026-6
21. Van der Linden M, Coyette F, Poitrenaud J, Kalafat M, Calicis F, Wyns C, et al. 16-item free recall/cued recall test (RL/RI-16). In: L'évaluation des Troubles de la Mémoire : Présentation de Quatre Tests de Mémoire Épisodique (Avec Leur Étalonnage). Liège: Solal Editeur (2004). p. 25–47.
25. Shin HB, Sheen H, Lee HY, Kang J, Yoon DK, Suh TS. Digital imaging and communications in medicine (DICOM) information conversion procedure for SUV calculation of PET scanners with different DICOM header information. Phys Med. (2017) 44:243–8. doi: 10.1016/j.ejmp.2017.05.063
26. Gonzalez-Escamilla G, Lange C, Teipel S, Buchert R, Grothe MJ. PETPVE12: an SPM toolbox for partial volume effects correction in brain PET – Application to amyloid imaging with AV45-PET. Neuroimage. (2017) 147:669–77. doi: 10.1016/j.neuroimage.2016.12.077
27. Della Rosa PA, Cerami C, Gallivanone F, Prestia A, Caroli A, Castiglioni I, et al. A Standardized [18 F]-FDG-PET template for spatial normalization in statistical parametric mapping of dementia. Neuroinform. (2014) 12:575–93. doi: 10.1007/s12021-014-9235-4
28. Ossenkoppele R, Schonhaut DR, Schöll M, Lockhart SN, Ayakta N, Baker SL, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. Brain. (2016) 139:1551–67. doi: 10.1093/brain/aww027
30. Frings L, Hellwig S, Spehl TS, Bormann T, Buchert R, Vach W, et al. Asymmetries of amyloid-β burden and neuronal dysfunction are positively correlated in Alzheimer's disease. Brain. (2015) 138:3089–99. doi: 10.1093/brain/awv229
33. Spehl TS, Hellwig S, Amtage F, Weiller C, Bormann T, Weber WA, et al. Syndrome-specific patterns of regional cerebral glucose metabolism in posterior cortical atrophy in comparison to dementia with lewy bodies and Alzheimer's disease-A [F-18]-Fdg pet study. J Neuroimaging. (2015) 25:281–8. doi: 10.1111/jon.12104
35. Singh TD, Josephs KA, Machulda MM, Drubach DA, Apostolova LG, Lowe VJ, et al. Clinical, FDG and amyloid PET imaging in posterior cortical atrophy. J Neurol. (2015) 262:1483–92. doi: 10.1007/s00415-015-7732-5
36. Ossenkoppele R, Schonhaut DR, Baker SL, O'Neil JP, Janabi M, Ghosh PM, et al. Tau, amyloid, and hypometabolism in a patient with posterior cortical atrophy. Ann Neurol. (2015) 77:338–42. doi: 10.1002/ana.24321
37. Cerami C, Crespi C, Della Rosa PA, Dodich A, Marcone A, Magnani G, et al. Brain changes within the visuospatial attentional network in posterior cortical atrophy. J Alzheimer's Dis. (2015) 43:385–95. doi: 10.3233/JAD-141275
38. Migliaccio R, Agosta F, Possin KL, Rabinovici GD, Miller BL, Gorno-Tempini ML. White matter atrophy in Alzheimer's disease variants. Alzheimers Dement. (2012) 8:S78–87. doi: 10.1016/j.jalz.2012.04.010
40. Firth NC, Primativo S, Marinescu R-V, Shakespeare TJ, Suarez-Gonzalez A, Lehmann M, et al. Longitudinal neuroanatomical and cognitive progression of posterior cortical atrophy. Brain. (2019) 147:2082–95. doi: 10.1093/brain/awz136
41. Phillips JS, Da Re F, Irwin DJ, McMillan CT, Vaishnavi SN, Xie SX, et al. Longitudinal progression of grey matter atrophy in non-amnestic Alzheimer's disease. Brain. (2019) 142:1701–22. doi: 10.1093/brain/awz091
44. Salmon E, Perani D, Herholz K, Marique P, Kalbe E, Holthoff V, et al. Neural correlates of anosognosia for cognitive impairment in Alzheimer's disease. Hum Brain Mapp. (2006) 27:588–97. doi: 10.1002/hbm.20203
45. Rosen HJ, Alcantar O, Rothlind J, Sturm V, Kramer JH, Weiner M, et al. Neuroanatomical correlates of cognitive self-appraisal in neurodegenerative disease. Neuroimage. (2010) 49:3358–64. doi: 10.1016/j.neuroimage.2009.11.041
46. Guerrier L, Le Men J, Gane A, Planton M, Salabert A-S, Payoux P, et al. Involvement of the cingulate cortex in anosognosia: a multimodal neuroimaging study in Alzheimer's disease patients. J Alzheimers Dis. (2018) 65:443–53. doi: 10.3233/JAD-180324
47. Shakespeare TJ, Yong KXX, Foxe D, Hodges J, Crutch SJ. Pronounced impairment of everyday skills and self-care in posterior cortical atrophy. J Alzheimers Dis. (2015) 43:381–4. doi: 10.3233/JAD-141071
48. Mendez MF, Ghajarania M, Perryman KM. Posterior cortical atrophy: clinical characteristics and differences compared to Alzheimer's disease. Dement Geriatr Cogn Disord. (2002) 14:33–40. doi: 10.1159/000058331
50. Leff AP, Schofield TM, Crinion JT, Seghier ML, Grogan A, Green DW, et al. The left superior temporal gyrus is a shared substrate for auditory short-term memory and speech comprehension: evidence from 210 patients with stroke. Brain. (2009) 132:3401–10. doi: 10.1093/brain/awp273
Keywords: posterior cortical atrophy, Alzheimer's disease, FDG-positron emission tomography, neuropsychological assessment, visuospatial and visuoperceptive dysfunction, patient's complaint
Citation: Guerrier L, Cransac C, Pages B, Saint-Aubert L, Payoux P, Péran P and Pariente J (2019) Posterior Cortical Atrophy: Does Complaint Match the Impairment? A Neuropsychological and FDG-PET Study. Front. Neurol. 10:1010. doi: 10.3389/fneur.2019.01010
Received: 14 May 2019; Accepted: 04 September 2019;
Published: 20 September 2019.
Edited by:Francesca Trojsi, University of Campania Luigi Vanvitelli, Italy
Reviewed by:Chiara Cerami, IRCCS Scientific Clinical Institutes Maugeri (ICS Maugeri), Italy
Bin Zhang, Guangzhou Medical University, China
Copyright © 2019 Guerrier, Cransac, Pages, Saint-Aubert, Payoux, Péran and Pariente. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.